References
- Kane JM, McGlashan TH. Treatment of schizophrenia. Lancet 1995; 346: 820–825
- Pantelis C, Barnes TRE. Drug strategies and treatment-resistant schizophrenia. The Australian and New Zealand Journal of Psychiatry 1996; 30: 20–38
- Owens MJ, Risch S. Craig. Atypical antipsychotics. Textbook of psychopharmacology, AF Schatzberg, CB Nemeroff. American Psychiatric Press, Washington 1995; 263–280
- Peacock LJ, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and haematologic monitoring in a system with liberal usage practices. Journal of Clinical Psychiatry 1994; 55: 44–49
- Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. Journal of Clinical Psychiatry 1996; 57: 395–397
- Morera AL, Barreiro P, Cano-Munoz JL. Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta Psychiatrica Scandinavica 1999; 99: 305–306
- Nyberg S, Eriksson B, Oxengtierna G, Halldin C, Farde L. Suggested minimal effective dose of risperidone, based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. American Journal of Psychiatry 1999; 156: 869–875
- McCarthy RH, Terkelsen KG. Risperidone augmentation of clozapine. Pharmacopsychiatry 1995; 28: 61–63